RUNX1 and acute myeloid leukemia: Histone deacetyases and DNA methyltransferases (DNMTs) are one of the targets that are recruited by RUNX1/ETO making HDAC and DNMT inhibitors a potential choice for targeting this sub-type of AML [83].